MB
DNTH icon

MPM BioImpact’s Dianthus Therapeutics DNTH Stock Holding History

MPM BioImpact’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40.9M Sell
420,002
-3,980
-0.9% -$348K 2.5% 16
2026
Q1 		$35.6M Buy
+423,982
New +$24.6M 2.75% 11

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

MPM BioImpact's DNTH Position: Q2 2026 in Review

MPM BioImpact reduced its Dianthus Therapeutics (DNTH) stake by 0.94% in Q2 2026, selling an estimated $348K and leaving 420,002 shares worth $40.9M. The position accounts for 2.5% of the portfolio, ranked #16.

MPM BioImpact first reported a position in DNTH in Q1 2026 and has held it in 2 quarters since. 269 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • MPM BioImpact held 420,002 shares of Dianthus Therapeutics worth $40.9M as of Q2 2026.
  • MPM BioImpact sold 3,980 Dianthus Therapeutics shares in Q2 2026, an estimated $348K.
  • Dianthus Therapeutics made up 2.5% of MPM BioImpact's portfolio in Q2 2026, its #16 holding.
  • MPM BioImpact first reported a position in Dianthus Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 269 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on MPM BioImpact's 13F filing for Q2 2026, filed 14 Aug 2026.